Skip header and navigation

Refine By

30 records – page 1 of 3.

The -1C to T polymorphism in the annexin A5 gene is not associated with the risk of acute myocardial infarction or sudden cardiac death in middle-aged Finnish males.

https://arctichealth.org/en/permalink/ahliterature53135
Source
Scand J Clin Lab Invest. 2005;65(2):133-40
Publication Type
Article
Date
2005
Author
K S Kaikkonen
S. Kakko
M L Kortelainen
J M Tapanainen
M J Savolainen
Y. Antero Kesäniemi
H V Huikuri
E R Savolainen
Author Affiliation
Division of Cardiology, Department of Internal Medicine, University of Oulu, Finland.
Source
Scand J Clin Lab Invest. 2005;65(2):133-40
Date
2005
Language
English
Publication Type
Article
Keywords
5' Untranslated Regions - genetics
Adult
Aged
Annexin A5 - genetics
Death, Sudden, Cardiac - epidemiology - etiology
Finland - epidemiology
Genetic markers
Genetic Predisposition to Disease
Genetic Screening
Humans
Male
Middle Aged
Myocardial Infarction - epidemiology - genetics
Polymorphism, Genetic
Research Support, Non-U.S. Gov't
Risk factors
Abstract
OBJECTIVE: A common polymorphism (-1C to T) in the translation initiation sequence of annexin A5 (ANV) gene has recently been associated with a decreased risk of acute myocardial infarction (AMI). The aim of the present study was to analyze the association between the ANV genepolymorphism and the risk of AMI and ischemic sudden cardiac death (SCD) in middle-aged Finnish males. MATERIAL AND METHODS: A case-control study involving three distinct groups of subjects was carried out: (1) victims of SCD (n=98), (2) survivors of AMI (n=212), and (3) randomly selected control subjects without any history of coronary heart disease (n=243). The ANV polymorphism was genotyped in each study group. RESULTS: Among the control group of healthy Finnish males the prevalence rates of the CC, CT, and TT genotypes were 83.1%, 15.2%, and 1.6%, respectively. Among the survivors of AMI, the prevalence rates of CC, CT, and TT were 79.7%, 20.3%, and 0%, respectively, and among the victims of SCD 83.7%, 16.3%, and 0%, respectively. No significant differences in the genotype or allele distributions were observed between the study groups. CONCLUSION: The -1C to T polymorphism in the ANV gene is not associated with the risk of AMI or SCD in middle-aged Finnish males.
PubMed ID
16025836 View in PubMed
Less detail

Acute myeloblastic leukaemia cells produce soluble interleukin 6 receptor by a mechanism of alternative splicing.

https://arctichealth.org/en/permalink/ahliterature21239
Source
Cytokine. 1998 Nov;10(11):860-7
Publication Type
Article
Date
Nov-1998
Author
M. Säily
P. Koistinen
K. Pulkki
A. Zheng
E R Savolainen
Author Affiliation
Department of Clinical Chemistry, University of Oulu, Finland.
Source
Cytokine. 1998 Nov;10(11):860-7
Date
Nov-1998
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Alternative Splicing
Female
Humans
Interleukin-6 - biosynthesis - genetics
Leukemia, Myelocytic, Acute - genetics - metabolism
Male
Middle Aged
RNA, Messenger - genetics
Research Support, Non-U.S. Gov't
Tumor Cells, Cultured
Abstract
The aim of the present work was to investigate whether acute myeloblastic leukaemia (AML) blast cells express a soluble (s) form of interleukin 6 (IL-6) receptor (R), and if they do, what is the mechanism of production. Eight AML patient cell lines and 25 primary AML blast cell samples were investigated. The cell lines secreted high quantities of sIL-6R into their culture medium when examined by enzyme-linked immunosorbent assay (ELISA). To determine whether sIL-6R is synthesized by a mechanism of alternative splicing, RNA was analysed from all the AML blast cell samples by using reverse transcription polymerase chain reaction. In this method, primer sites flanking the transmembrane domain were utilized and the alternatively spliced IL-6R mRNA was distinguished from the non-spliced transcript form by size. All the cell lines and 64% of the primary blast cell samples expressed the alternatively spliced IL-6R mRNA. To confirm the phenomenon of alternative splicing at protein level, cytoplasmic protein fractions of the cell lines were investigated by using a sensitive adaptation of the Western blot method. All the cell lines expressed two IL-6R proteins sized 80 and 50 kDa and corresponding to the membraneous and soluble forms of IL-6R, respectively. In conclusion, the results obtained at both mRNA and protein levels strongly support alternative splicing as a mechanism of sIL-6R production in AML. Because sIL-6R modulates the effects of IL-6 on target cells, differences in sIL-6R expression levels may partially explain the previously observed diversity in IL-6-induced growth responses in AML
Notes
Comment In: Cytokine. 2000 Apr;12(4):42210805228
PubMed ID
10025979 View in PubMed
Less detail

All-trans retinoic acid combined with interferon-alpha effectively inhibits granulocyte-macrophage colony formation in chronic myeloid leukemia.

https://arctichealth.org/en/permalink/ahliterature22740
Source
Leuk Res. 1996 Mar;20(3):243-8
Publication Type
Article
Date
Mar-1996
Author
A. Zheng
E R Savolainen
P. Koistinen
Author Affiliation
Department of Internal Medicine, University of Oulu, FInland.
Source
Leuk Res. 1996 Mar;20(3):243-8
Date
Mar-1996
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Cell Division - drug effects
Female
Hematopoietic Stem Cells - drug effects
Humans
Interferon-alpha - administration & dosage - pharmacology - therapeutic use
Leukemia, Myeloid, Chronic - drug therapy - pathology
Male
Middle Aged
Tretinoin - administration & dosage - pharmacology - therapeutic use
Abstract
We investigated the effect of all-trans retinoic acid (ATRA) alone and in combination with interferon-alpha (IFN-alpha) on the granulocyte-macrophage (GM) colony formation of peripheral blood progenitors isolated from patients with chronic myeloid leukemia (CML) (n = 12) or other myeloproliferative disorders (n = 10) as well as from healthy controls (n = 7). The ATRA or IFN-alpha alone inhibited slightly, but not significantly, the GM colony growth in CML. Granulocyte-macrophage colony formation decreased significantly (P
PubMed ID
8637219 View in PubMed
Less detail

An association between mitochondrial function and all-trans retinoic acid-induced apoptosis in acute myeloblastic leukaemia cells.

https://arctichealth.org/en/permalink/ahliterature21054
Source
Br J Haematol. 1999 Apr;105(1):215-24
Publication Type
Article
Date
Apr-1999
Author
A. Zheng
P. Mäntymaa
M. Säily
T. Siitonen
E R Savolainen
P. Koistinen
Author Affiliation
Departments of Internal Medicine; Clinical Chemistry, University of Oulu, Oulu, Finland.
Source
Br J Haematol. 1999 Apr;105(1):215-24
Date
Apr-1999
Language
English
Publication Type
Article
Keywords
Apoptosis - drug effects
Cell Division
Cytochrome c Group - metabolism
Down-Regulation
Gene Expression
Genes, bcl-2 - physiology
Humans
Leukemia, Myelocytic, Acute - metabolism - pathology - physiopathology
Mitochondria - physiology
Research Support, Non-U.S. Gov't
Tretinoin - pharmacology
Tumor Cells, Cultured
Abstract
The present study investigated whether all-trans retinoic acid (ATRA)-induced apoptosis in acute myeloblastic leukaemia (AML) is related to changes in mitochondrial function. Two human AML cell lines, OU-AML-3 and OU-AML-7, known to be inducible to time-dependent apoptosis of varying degrees by ATRA, were used. Apoptosis induced by ATRA was shown to be a slow event. It was detected by the DNA electrophoretic method and cytofluorimetrical annexin V assay after 48 h exposure, and by morphology and polyADPribose polymerase (PARP) cleavage after 72 h exposure of AML cells to ATRA. The efflux of mitochondrial cytochrome c to cytosol was notable in Western blotting after 48 h exposure of the cells to ATRA and was observed before the drop in the mitochondrial membrane potential, which only took place after 72 h exposure, when measured by flow cytometry and a JC-1 probe. The apoptotic events in mitochondria were more evident in the OU-AML-3 than the OU-AML-7 cell line. This might relate to the different bcl-2 contents of the cell lines: the basic bcl-2 levels of the OU-AML-7 cell line were almost twofold compared to that of the OU-AML-3 cell line, as analysed by the ELISA method. However, both of the cell lines showed progressive down-regulation of bcl-2, which began after 12-24 h exposure of the cells to ATRA as determined by ELISA, Western blotting and flow cytometry. The present results show that mitochondria have a role in ATRA-induced apoptosis in AML cells and down-regulation of bcl-2 is related to it. In view of the previously published studies, the present results underline the fact that the timing of apoptotic events, such as fragmentation of DNA, externalization of phosphatidylserine, cytochrome c efflux, change in mitochondrial membrane potential and cleavage of PARP, are, to a notable extent, cell type and inducer-dependent.
PubMed ID
10233386 View in PubMed
Less detail

Cellular redox state and its relationship to the inhibition of clonal cell growth and the induction of apoptosis during all-trans retinoic acid exposure in acute myeloblastic leukemia cells.

https://arctichealth.org/en/permalink/ahliterature20578
Source
Haematologica. 2000 Mar;85(3):238-45
Publication Type
Article
Date
Mar-2000
Author
P. Mäntymaa
T. Guttorm
T. Siitonen
M. Säily
E R Savolainen
A L Levonen
V. Kinnula
P. Koistinen
Author Affiliation
Department of Clinical Chemistry, University of Oulu, Oulu, Finland.
Source
Haematologica. 2000 Mar;85(3):238-45
Date
Mar-2000
Language
English
Publication Type
Article
Keywords
Apoptosis - drug effects
Cell Division - drug effects
Clone Cells - drug effects - physiology
Glutathione - drug effects - metabolism
Humans
Leukemia, Myelocytic, Acute - pathology - physiopathology
Oxidants - pharmacology - physiology
Oxidation-Reduction - drug effects
Peroxides - metabolism
Reactive Oxygen Species - metabolism - physiology
Research Support, Non-U.S. Gov't
Superoxide Dismutase - drug effects
Tretinoin - pharmacology - physiology
Tumor Cells, Cultured - drug effects - physiology
gamma-Glutamyl Hydrolase - drug effects - metabolism
Abstract
BACKGROUND AND OBJECTIVE: All-trans retinoic acid (ATRA) induces growth arrest and apoptosis in acute myeloblastic leukemia (AML) cells. Since cellular redox state regulates these events, we were interested in studying whether it has any role in the responsiveness of AML cells to ATRA. DESIGN AND METHODS: Two human AML cell lines, the ATRA-sensitive OU-AML-3, and the ATRA-resistant OU-AML-7, were used as models. Clonogenic cell culture assay, annexin V method, and measurement of mitochondrial membrane potential were used for the determination of cell growth and apoptosis. Peroxide formation was analyzed by flow cytometry, glutathione and g-glutamylcysteine synthetase (g-GCS) activity was determined spectrophotometrically, and the expression of manganese superoxide dismutase (MnSOD) by Western blotting. RESULTS: ATRA inhibited clonogenic cell growth and induced apoptosis particularly in OU-AML-3 cells. The OU-AML-7 cells had a higher basal level of glutathione and g-GCS activity than the OU-AML-3 cells. ATRA enhanced the generation of peroxides after 24h exposure, which was more prominent in the sensitive than the resistant cell line and was not preventable by N-acetyl-L-cysteine. ATRA also increased the activity of g-GCS, which was associated with increased intracellular glutathione in the resistant cell line, while the glutathione level was maintained in the sensitive cell line. During ATRA exposure, MnSOD was induced in the sensitive cell line, but not until after 72 h. Buthionine sulfoximine significantly increased the inhibitory effect of ATRA on colony formation in both cell lines, but only marginally enhanced the effect of ATRA on the induction of apoptosis. INTERPRETATION AND CONCLUSIONS: The balance between oxidative and antioxidative actions of ATRA, as well as the basal redox state of the cells seem to have a definite influence on the responsiveness of AML cells to ATRA.
PubMed ID
10702810 View in PubMed
Less detail

c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease.

https://arctichealth.org/en/permalink/ahliterature19966
Source
Eur J Cancer. 2001 Feb;37(3):347-54
Publication Type
Article
Date
Feb-2001
Author
A. Jukkola
R. Bloigu
Y. Soini
E R Savolainen
K. Holli
G. Blanco
Author Affiliation
Department of Oncology, University of Oulu, Finland.
Source
Eur J Cancer. 2001 Feb;37(3):347-54
Date
Feb-2001
Language
English
Publication Type
Article
Keywords
Antineoplastic Agents, Hormonal - therapeutic use
Blotting, Southern
Breast Neoplasms - drug therapy - genetics - metabolism
Disease-Free Survival
Female
Genes, erbB-2 - genetics
Humans
Immunohistochemistry
Polymerase Chain Reaction - methods
Prognosis
Receptor, erbB-2 - metabolism
Regression Analysis
Retrospective Studies
Treatment Outcome
Abstract
The aim of this work was to evaluate the prognostic and predictive values of c-erbB-2 in breast cancer. 650 patients were enrolled. The amplification/overexpression of c-erbB-2 from fresh frozen or paraffin-embedded breast tumour tissue samples was analysed by polymerase chain reaction (PCR) technique (75%), immunohistochemically (17%) or by Southern blot analysis (8%). 126 patients (19%) were positive for c-erbB-2. 148 patients developed metastatic disease, but only 35 were positive for c-erbB-2. Positivity for c-erbB-2 was significantly associated with node positivity, large tumour size, high grade of malignancy, low receptor status, postmenopausal status, and with a shorter overall survival. In multivariate regression analysis, only tumour size and nodal involvement were risk factors for poor survival when analysed separately together with c-erbB-2 and receptor status. Metastatic patients with c-erbB-2 positivity had a significantly shorter survival and disease-free survival (DFS) than the c-erbB-2-negative patients. 29 advanced patients with c-erbB-2 positivity showed a poor response rate to hormonal, non-anthracycline-based and anthracycline-based therapies. Positivity for the c-erbB-2 is a poor prognostic factor in breast cancer, but it also emerges as predictive of the response to hormonal or chemotherapy treatment once the disease has recurred.
PubMed ID
11239756 View in PubMed
Less detail

Complex effects of interleukin 6 on clonogenic blast cell growth in acute myeloblastic leukemia.

https://arctichealth.org/en/permalink/ahliterature22326
Source
Acta Haematol. 1997;98(1):14-21
Publication Type
Article
Date
1997
Author
P. Koistinen
M. Säily
N. Poromaa
E R Savolainen
Author Affiliation
Department of Internal Medicine, University of Oulu, Finland.
Source
Acta Haematol. 1997;98(1):14-21
Date
1997
Language
English
Publication Type
Article
Keywords
Adult
Aged
Cell Division
Clone Cells - pathology
Granulocyte Colony-Stimulating Factor - pharmacology
Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology
Humans
Interleukin-3 - pharmacology
Interleukin-4 - pharmacology
Interleukin-6 - pharmacology
Leukemia, Myelocytic, Acute - pathology
Middle Aged
Research Support, Non-U.S. Gov't
Stem Cell Factor - pharmacology
Tumor Cells, Cultured
Abstract
The present in vitro study shows how interleukin (IL)-6 modulates clonogenic blast cell growth in complex ways in acute myeloblastic leukemia when used either as a single factor or in different hematopoietic growth factor combinations. In the presence of IL-6, the colony numbers in culture assay decreased to 50 +/- 29% from the basal values (p
PubMed ID
9210908 View in PubMed
Less detail

Congenital nephrotic syndrome of the Finnish type maps to the long arm of chromosome 19.

https://arctichealth.org/en/permalink/ahliterature59399
Source
Am J Hum Genet. 1994 May;54(5):757-64
Publication Type
Article
Date
May-1994
Author
M. Kestilä
M. Männikkö
C. Holmberg
G. Gyapay
J. Weissenbach
E R Savolainen
L. Peltonen
K. Tryggvason
Author Affiliation
Biocenter, University of Oulu, Finland.
Source
Am J Hum Genet. 1994 May;54(5):757-64
Date
May-1994
Language
English
Publication Type
Article
Keywords
Cell Line
Cells, Cultured
Chromosome Mapping
Chromosomes, Human, Pair 19
DNA, Satellite - analysis
Female
Finland - epidemiology
Genes, Recessive
Humans
Incidence
Infant, Newborn
Linkage (Genetics)
Lymphocytes - metabolism
Male
Nephrotic Syndrome - congenital - epidemiology - genetics
Pedigree
Polymorphism, Genetic
Recombination, Genetic
Research Support, Non-U.S. Gov't
Skin - metabolism
Abstract
Congenital nephrotic syndrome of the Finnish type (CNF) is an autosomal recessive disease that is characterized by massive proteinuria and nephrotic syndrome at birth. CNF represents a unique, apparently specific dysfunction of the renal basement membranes, and the estimated incidence of CNF in the isolated population of Finland is 1 in 8,000 newborns. The basic defect is unknown, and no specific biochemical defect or chromosomal aberrations have been described. Here we report the assignment of the CNF locus to 19q12-q13.1 on the basis of linkage analyses in 17 Finnish families. Multipoint analyses and observed recombination events place the CNF locus between multiallelic markers D19S416 and D19S224, and the significant linkage disequilibrium observed suggests that the CNF gene lies in the immediate vicinity of the markers D19S224 and D19S220.
PubMed ID
8178817 View in PubMed
Less detail

Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92.

https://arctichealth.org/en/permalink/ahliterature18860
Source
Leukemia. 2002 Oct;16(10):2037-45
Publication Type
Article
Date
Oct-2002
Author
T M Calero Moreno
G. Gustafsson
S. Garwicz
D. Grandér
G K Jonmundsson
B-M Frost
A. Mäkipernaa
O. Rasool
E-R Savolainen
K. Schmiegelow
S. Söderhäll
K. Vettenranta
F. Wesenberg
S. Einhorn
M. Heyman
Author Affiliation
Research Laboratory of Radiumhemmet, CCK Karolinska Hospital, Stockholm, Sweden.
Source
Leukemia. 2002 Oct;16(10):2037-45
Date
Oct-2002
Language
English
Publication Type
Article
Keywords
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Base Sequence
Blotting, Southern
Cell Cycle Proteins - genetics
Child
Child, Preschool
Cyclin-Dependent Kinase Inhibitor p15
Cyclin-Dependent Kinase Inhibitor p16 - genetics
DNA Primers
Female
Gene Deletion
Humans
Infant
Leukemia, Lymphocytic, Acute, L1 - drug therapy - genetics - pathology
Male
Multivariate Analysis
Polymorphism, Single-Stranded Conformational
Recurrence
Research Support, Non-U.S. Gov't
Retrospective Studies
Treatment Outcome
Tumor Suppressor Protein p14ARF - genetics
Tumor Suppressor Proteins
Abstract
Inactivation of the Ink4 gene locus locus on 9p comprising the tumour suppressor gene p16ink4a and its neighbours p14ARF and p15ink4b is common in childhood acute lymphoblastic leukaemia (ALL), but the prognostic significance is controversial. DNA from 230 patients was retrospectively analysed by Southern blotting, single strand conformation polymorphism (SSCP) and sequencing techniques. The results were correlated with clinical characteristics and outcome. One hundred and ninety-four fully analysed patients, similarly treated using the Nordic NOPHO-86 or the current NOPHO-92 protocols, were included in the outcome analysis. Deletions approached a minimally deleted region between the p16ink4a and p15ink4b genes, making the p14ARF gene the most commonly deleted coding sequence. Bi-allelic deletion was associated with high white blood cell count (WBC) (P
PubMed ID
12357355 View in PubMed
Less detail

Development of permanent national register of blood component use utilizing electronic hospital information systems.

https://arctichealth.org/en/permalink/ahliterature167928
Source
Vox Sang. 2006 Aug;91(2):140-7
Publication Type
Article
Date
Aug-2006
Author
R. Palo
T. Ali-Melkkilä
R. Hanhela
V. Jäntti
T. Krusius
E. Leppänen
E K Mahlamäki
V. Perhoniemi
A. Rajamäki
J. Rautonen
M. Salmenperä
H. Salo
I. Salonen
E-R Savolainen
S. Sjövall
M. Suistomaa
M. Syrjälä
A. Tienhaara
M. Vähämurto
T. Mäki
Author Affiliation
Finnish Red Cross Blood Service, Helsinki, Finland. riikka.palo@hus.fi
Source
Vox Sang. 2006 Aug;91(2):140-7
Date
Aug-2006
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Blood Component Transfusion - utilization
Child
Child, Preschool
Feasibility Studies
Female
Finland
Geographic Information Systems - statistics & numerical data
Hospital Information Systems - statistics & numerical data
Humans
Infant
Infant, Newborn
Male
Middle Aged
Registries - statistics & numerical data
Retrospective Studies
Abstract
We wanted to establish a permanent national database system, which can be utilized to study transfusion recipients and blood use in Finland.
A regularly updated register for permanent use was developed. To study the usability of the database, years 2002 and 2003 were further analysed. Database included all transfused patients in major blood-transfusing hospitals from four university and five central hospital districts managing altogether 63% of Finnish inpatient hospital episodes.
Audit of gathered data reveal 96.8% match in adult blood components with Finnish Red Cross, Blood Service sales figures. Model data set includes 59,535 transfused patients (44.3% men and 55.7% women) having received 529,104 blood components. Half of all blood units were transfused in connection with surgical operations. Most of the blood recipients were elderly (51.6% are over 64 years of age). Blood-component use and transfusion-related costs varied widely between hospitals.
Hospital data managing systems can be useful for creating a population-based database system to monitor and compare transfusion practices. This record provides information about transfusion epidemiology for transfusion professionals, hospital management, and hospital administration.
PubMed ID
16907875 View in PubMed
Less detail

30 records – page 1 of 3.